Threonine 348 regulates the subcellular localization of PTEN
Thr348 in the C2 domain is a key contributor to PTEN subcellular localization. The PTEN350 fragment and PTENA4 accumulated in the nucleus, whereas PTENK13R,A4 predominantly localized to the plasma membrane. In contrast, substitution of Thr348 with Asp (T348D) disrupted these characteristic localization patterns, resulting in predominant cytoplasmic ...
Takashi Kato, Suzu Tanaka, Miyu Ohashi
wiley +1 more source
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study). [PDF]
Gariazzo E +49 more
europepmc +1 more source
A minimal cellulosome‐like system in Cellulosilyticum lentocellum
Cellulose‐degrading bacteria typically use cellulosomes, large multi‐enzyme complexes on a scaffold protein. In Cellulosilyticum lentocellum, we characterise a far smaller arrangement, a single scaffold bound to one cellulase through a single cohesin‐dockerin interaction.
John Allan +2 more
wiley +1 more source
Clinical Outcomes of Second-Line Amrubicin and Platinum-Based Doublet Chemotherapy in Patients with Extrapulmonary Neuroendocrine Carcinoma: A Multicenter Retrospective Study. [PDF]
Yamakita N +9 more
europepmc +1 more source
Cell surface CD11c as a neutrophil aging marker molecule
Cell surface CD11chi neutrophils were more aged and had better phagocytic function than CD11c−/lo neutrophils. Transcriptomic analysis of CD11chi neutrophils and CD11c−/lo neutrophils in pediatric population showed that the most difference was seen in infants.
Sophia Koutsogiannaki +5 more
wiley +1 more source
Treatment patterns and safety outcomes after splenectomy or thrombopoietin receptor agonists as second-line therapy for immune thrombocytopenia: Korean claims-based study. [PDF]
Lim HJ +7 more
europepmc +1 more source
Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report. [PDF]
Otsuka S, Hiraoka K, Iwashiro N.
europepmc +1 more source
Navigating second-line therapy after immunotherapy in advanced HCC☆. [PDF]
Vogel A +3 more
europepmc +1 more source
Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response. [PDF]
Kuzuya T +10 more
europepmc +1 more source

